From diabetes to heart disease, the obesity drug Zepbound has been shown to have positive effects for other health ailments. Now, the company has a trial pointing to reduced sleep apnea severity. The health care giant’s stock has bounced on every drug-pipeline update, so Ben Lichtenstein decided to focus on the technical patters on Chart of the Day: Eli Lilly (LLY)